Mary Caffrey

The breach comes as the Trump administration hopes to rely more heavily on professionals to assist consumers during open enrollment.

Researchers have created a database that shows how 409 different tumor cells respond to 122 therapies, which will allow clinical trials to proceed for this aggressive blood cancer.

Finding a place for value-based payment with the fast paced innovation in oncology.

The idea for putting drug prices in TV ads was part of the blueprint, American Patients First. The pharmaceutical industry opposes the plan on First Amendment grounds.

As CareMore Health touts success in keeping Medicaid patients out of the emergency department, a separate report shows lack of access to Medicaid keeps the poor in many states from seeking care.

The analysis of data from EMPA-REG OUTCOME arrives as the FDA weighs the future of these large trials.

The deal could lead to the transformation of CVS' drug stores into retail medical centers. The American Medical Association opposes the plan.

Research at the University of Washington is exploring the possibility of triggering one gene to take over the function of another with a common mutation that triggers acute lymphoblastic leukemia.

Patient preference should be considered because medications don't work if adherence is poor, the experts noted.

The dual inhibitor first blocks 2 kinases that are known to aid the growth of malignant B cells, and then it disrupts the microenvironment that supports tumor growth.

Pharmacy benefit managers (PBMs) will have to disclose some information about their compensation and relationships with payers.

The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.

For 2017, New Jersey's largest insurer made particularly good progress in certain diabetes measures and in cancer screenings.

James P. Allison, PhD, and Tasuku Honjo, MD, PhD, led the basic science experiments that showed the potential of checkpoint inhibitors, creating a fourth pillar in the treatment of cancer.

POSTERS AT THE 2018 American Association of Diabetes Educators (AADE) Annual Conference covered updates on new therapies and technology, strategies to help patients overcome fear of using insulin, and innovations in diabetes self-management education and support. Following are a few snapshots of the research presented at AADE.

Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.

Livongo’s technology is built around the idea that a person living with diabetes must make multiple decisions every day, and the cumulative effect of all those decisions drives outcomes.

A profile of a program that calls for residents in a rural area to become full partners in managing their type 2 diabetes, and in the process bring changes to their community.

Employers who have been disappointed in the past with wellness programs want to see evidence of patient engagement and how this translates into savings.

Advocates for keeping Medicare as it is were joined by a well-known pollster to discuss that voters are concerned about out-of-pocket costs, including what they pay for prescription drugs, as the 2018 midterm elections approach.

Heart failure hospitalization has been a target for accountable care organizations seeking to find ways to cut costs from the healthcare system. But it remains to be seen how many of the estimated 2 million patients would gain access to the device if it received an expanded indication and payer coverage.

Full results from the cardiovascular outcomes trial for dapagliflozin (Farxiga) will be presented at the American Heart Association annual meeting in November.

AARP and other groups reacted strongly to reports that the pharmaceutical industry was using efforts to combat the opioid crisis to roll back an agreement to close the coverage gap in Medicare Part D.

A series of experiments identified both "good" and "bad" gut bacteria, suggesting possible treatments for obesity.

The bill is part of President Donald Trump's blueprint to rein in prescription drug prices, and advocates see it as a small step in the right direction.

Lower socioeconomic status is associated with poor survival in lymphoma.

The study by the National Institute on Aging produced a few surprises and was stopped early when aspirin showed no benefit.

The announcement comes with word from FDA touting the effectiveness of its efforts to advance digital health regulatory pathways.

The application is based on results presented in March at the 67th Scientific Session of the American College of Cardiology.

One patient saw a complete response, and the therapy was well tolerated, especially compared with the adverse effects sometimes seen with chimeric antigen receptor (CAR) T-cell treatment in blood cancers thus far.